Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Work In Process (2023 - 2025)

Historic Work In Process for Verrica Pharmaceuticals (VRCA) over the last 3 years, with Q2 2025 value amounting to $523000.0.

  • Verrica Pharmaceuticals' Work In Process fell 2342.61% to $523000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $523000.0, marking a year-over-year decrease of 2342.61%. This contributed to the annual value of $664000.0 for FY2024, which is 3634.5% up from last year.
  • According to the latest figures from Q2 2025, Verrica Pharmaceuticals' Work In Process is $523000.0, which was down 2342.61% from $179000.0 recorded in Q1 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Work In Process ranged from a high of $750000.0 in Q3 2024 and a low of $179000.0 during Q1 2025
  • Its 3-year average for Work In Process is $564857.1, with a median of $664000.0 in 2024.
  • Its Work In Process has fluctuated over the past 5 years, first soared by 3634.5% in 2024, then plummeted by 7320.36% in 2025.
  • Verrica Pharmaceuticals' Work In Process (Quarter) stood at $487000.0 in 2023, then skyrocketed by 36.34% to $664000.0 in 2024, then dropped by 21.23% to $523000.0 in 2025.
  • Its last three reported values are $523000.0 in Q2 2025, $179000.0 for Q1 2025, and $664000.0 during Q4 2024.